There is little doubt that the field of cell cycle control, and its intimate links with cancer and biological responses to DNA damage, represent one of the most dynamic and fruitful areas of contemporary biomedical research. The value and emerging impact of this field is perhaps best documented by the fact that the Nobel prize for physiology and medicine this year has been awarded to acknowledge the seminal discoveries about the eukaryotic cell cycle, and their potential to be exploited in the ongoing war against cancer. Given the highly topical nature and rapid pace of new findings in this field, any attempt to summarize the recent major advances in cell cycle and cancer research is a valuable one, yet requires a very brave decision. The book on 'Cell Cycle Checkpoints and Cancer', edited by Mikhail Blagosklonny, is such a brave attempt, and a very successful one indeed. The editor himself is one of the recognized leading experts active in research at the border between cell cycle control, DNA damage checkpoints, and molecular oncogenesis. He succeeded in recruiting outstanding scientists in this field, to contribute a series of chapters on the key aspects of cell cycle checkpoints and their relevance to basic as well as applied oncological research.
The book starts with a preface by the editor, on Advances in Research and Challenges in Therapy, which explains the motivation behind this work, and highlights some of the key discoveries in the field which facilitate the recent attempts to target cancer-associated cell cycle defects in search for novel therapies. A series of 14 chapters on complementary topics follows (see below), each written by one or several experts in that specific area, and each providing a separate list of critical references which are very useful. Despite the fact that some of the chapters contain an abstract, while others do not, the whole collection is well coordinated and balanced. The book contains some 250 pages of text and informative figures and models, and ends with an index of key symbols, to help readers to quickly identify information on specific cell cycle regulators and important phenomena.
The first two chapters are devoted to mitogenic signalling cascades, focusing on autocrine production of cytokines and growth factors (Chapter 1), and the signal transduction from growth factor receptors to cell cycle machinery, illustrating also the links between cell cycle progression and apoptotic pathways (Chapter 2). Chapter 3 discusses the emerging molecular basis of the so-called restriction point in advanced G1 phase, when cells stimulated by mitogens make the commitment to replicate DNA and complete the initiated round of the cell division cycle. The restriction point is almost universally defective in cancer cells, which further emphasizes the importance of the G1/S transition control.
The error-free execution of the successive cell cycle events, and the integrity of the chromosomal DNA to be passed on daughter cells, are ensured by a complex network of surveillance mechanisns collectively known as cell cycle checkpoints. In Chapter 4, the principles of cell cycle checkpoints activated in response to DNA damage are outlined, along with their significance in protection against cancer. The following chapter highlights the evolutionary conservation of the cell cycle checkpoints from yeast to human, and focuses on yeast checkpoints which monitor the DNA synthesis (DNA replication checkpoint) and mitotic events, in particular spindle assembly, and exit from mitosis.
Chapter 6 summarizes the regulation and function of the p53 tumour suppressor, one of the key checkpoint regulators. The authors also discuss the importance of subcellular trafficking in p53 biology, and the highly debated issue of how the p53-mediated checkpoint response makes the choice between cell cycle arrest and cell death. Another key checkpoint regulator, the BRCA1 tumour suppressor which is targeted in some common cancers, is the subject discussed in Chapter 7. BRCA1 emerges as one of the central integrating elements of cell cycle checkpoints and DNA repair, operating through protein-protein interactions with multiple cell cycle and checkpoint proteins, also discussed here.
Along with p53, mutations of the FHIT tumour suppressor are among the most common cancer-associated defects in human malignancies. Chapter 8 explains the role of FHIT in carcinogenesis, including the basis of chromosomal aberrations and other mechanisms which deregulate this tumour suppressor, and its emerging biological functions. One of the less commonly discussed, yet fundamental cellular responses, is mechanisms of defense against hypoxia. Chapter 9 summarizes these mechanisms, the ability of hypoxia to induce cell cycle arrest through inhibiting the activity of cyclin-dependent kinases, and the likely involvement of these mechanisms in resistance to chemotherapy. The next chapter further highlights the importance of cell cycle checkpoints in the outcome of anticancer therapy, with particular emphasis on the G2 checkpoint. Both the early (activation) and late (maintenance) steps of the G2 checkpoint response are discussed, as are the possible ways to modulate this checkpoint, and the prospects of such checkpoint manipulations for optimizing cancer therapy.
Chapter 11 returns to p53, yet from the specific point of apoptosis regulation by p53, and the potential relevance of p53 status in clinical oncology. The p53 tumour suppressor, and its critical downstream target, the p21 inhibitor of cyclindependent kinases, are also discussed in Chapter 12, this time focusing on non-apoptotic cellular responses to anticancer agents. These include phenomena such as mitotic catastrophe and cellular senescence, whose underlying molecular principles and potential exploitation in cancer treatment are discussed.
Arguably, the currently most promising avenue to apply the new knowledge about cell cycle control in cancer treatment, is the search for small molecule inhibitors of cell cycle regulatory enzymes, in particular the cyclin-dependent kinases. Properties of, and initial experience with, the most promising classes of such inhibitors, both targeting the CDKs and non-CDK checkpoint kinases, are presented in Chapter 13. Finally, Chapter 14 considers a broader view of the current and future attempts to explore the cell cycle mechanisms as targets in drug discovery. Defects of cell cycle control and checkpoint pathways in cancer cells are widely regarded as a potential Achilles' heal of tumour cells, and great efforts in both academic research laboratories and the pharmaceutical industry are currently devoted to turn these molecular differences to the benefit of patients.
In summary, among the most valuable features of this exciting book are high-quality overviews guaranteed by internationally recognized expert contributors, rapid publication to ensure the book is timely, and a specific, highly desirable focus on the area of convergence between basic cell cycle research and oncology. The latter also includes approaches to design more effective treatment strategies. These features ensure that this book is not one of those whose contents is inferior to the many journal reviews, and out of date by the Leukemia time it is published. The specific niche covered by this book is a lucky choice, since papers in this area are scattered through many different journals, and it is impossible to keep track and make an up-to-date synthesis of these rapidly emerging discoveries. In short, 'Cell Cycle Checkpoints and Cancer' offers very informative and inspiring reading. The book will appeal to a wide audience of students, physicians and scientists in diverse disciplines, both in basic research and the pharmaceutical industry. I have learned a great deal from reading this useful and enjoyable work, and I hope so will you.
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